Q3 2025 Earnings Call Transcript May 14, 2025 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $0.2, ...

Aytu BioPharma Inc (AYTU) reports significant revenue growth and operational income, despite challenges in gross margins and acquisition valuations.

Third Quarter 2025 Results Key Financial Results Revenue: US$18.5m (up 2.6% from ...

Greetings. And welcome to the Aytu BioPharma Fiscal 2025 Q3 Earnings Call. At this time, all participants are in a listen-only. [Operator Instructions] Please note, this conference is being recorded.

Aytu BioPharma reported a strong financial performance in Q3 FY2025, with significant revenue growth and a return to profitability. The company’s stock surged 52.6% in aftermarket trading ...

About Aytu BioPharma, Inc. This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of ...

These 10 undervalued real estate stocks pay dividends and trade at attractive prices. We sell different types of products and services to both investment professionals and individual investors ...

Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 million up 32% year-over-yearCompany to ...

Aytu BioPharma reported a strong financial performance in Q3 FY2025, with significant revenue growth and a return to profitability. The company’s stock surged 52.6% in aftermarket trading, reflecting ...

DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its ...

2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for ...